Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (366 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | LIC MF Nifty 50 Index Fund |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹160.92 |
| 26 Aug 2009 | ₹116.00 |
| 08 May 2011 | ₹137.46 |
| 17 Jan 2013 | ₹150.65 |
| 30 Sep 2014 | ₹198.89 |
| 11 Jun 2016 | ₹203.46 |
| 21 Feb 2018 | ₹256.47 |
| 04 Nov 2019 | ₹295.57 |
| 16 Jul 2021 | ₹392.99 |
| 28 Mar 2023 | ₹418.76 |
| 08 Dec 2024 | ₹609.97 |
| 20 Aug 2026 | ₹600.90 |
| Metric | LIC · Regular NAV ₹134.03 Very High risk ★★★☆☆ | Category median Index Funds · 366 funds |
|---|---|---|
| -3.29% | +5.43% | |
| +7.90% | +8.41% | |
| +8.15% | +8.95% | |
| +10.78% | +11.28% | |
| +9.20% | +7.40% | |
| +6.48% | — | |
| +10.38% | +11.37% | |
| +10.41% | +13.00% | |
| +10.33% | +11.07% | |
| Risk | ||
| 13.18% | 13.88% | |
| 0.11 | 0.25 | |
| 0.15 | 0.35 | |
| -60.66% | -16.66% | |
| Nifty 50 | — | |
| +0.07% | +0.30% | |
| 1.00 | 1.00 | |
| 99.8% | 101.3% | |
| 99.2% | 98.8% | |
| 1.06% | 0.96% | |
| ₹358.29Cr | ₹182.17Cr | |
| 0.25% | — | |
| None | — | |
| ₹200 | — | |
| ₹5.00K | — | |
| 31% | 35% | |
| Sumit Bhatnagar · 2.9y | — | |
| 03 Apr 2006 | — | |
| 50 | — | |
| 53.6% | — | |
| 0.3% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.